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Infection with the bacterial pathogen Mycobacterium tuberculosis
imposes an enormous burden on global public health. New anti-
biotics are urgently needed to combat the global tuberculosis
pandemic; however, the development of new small molecules is
hindered by a lack of validated drug targets. Here, we describe the
identification of a 4,6-diaryl-5,7-dimethyl coumarin series that kills
M. tuberculosis by inhibiting fatty acid degradation protein D32
(FadD32), an enzyme that is required for biosynthesis of cell-wall
mycolic acids. These substituted coumarin inhibitors directly in-
hibit the acyl-acyl carrier protein synthetase activity of FadD32.
They effectively block bacterial replication both in vitro and in
animal models of tuberculosis, validating FadD32 as a target for
antibiotic development that works in the same pathway as the
established antibiotic isoniazid. Targeting new steps in well-vali-
dated biosynthetic pathways in antitubercular therapy is a
powerful strategy that removes much of the usual uncertainty
surrounding new targets and in vivo clinical efficacy, while cir-
cumventing existing resistance to established targets.
Tuberculosis is one of the leading causes of death by infectiousdiseases worldwide, killing an estimated 2 million people
annually (1). The emergence of multidrug resistant (MDR) and
extensively drug resistant (XDR) strains of Mycobacterium
tuberculosis has increased the threat that this disease poses to
global public health. Despite a few recent successes (2–4), there
are relatively few candidates in the drug development pipeline
for tuberculosis. Although there is a substantial amount of ge-
netic data defining essential genes in M. tuberculosis (5, 6), little
is known about which of the approximately ∼600 predicted es-
sential proteins are possible drug targets. To meet current and
future therapeutic needs, the discovery and validation of new
drug targets and novel chemical structures that target these
proteins is a critical priority.
Recent years have seen an enormous increase in efforts to
discover new molecules with novel mechanisms using both whole-
cell screening and mechanism-based biochemical approaches (7);
however, progress in validating new targets has been slow.
Although there are numerous reports of small molecules with
activity against M. tuberculosis, target identification remains a
significant challenge. Similarly, although many potential targets
have been proposed based on genetic and biochemical experi-
ments, chemical and biological validation that these targets can
be inhibited by drug-like molecules with efficacy in vivo is for
the most part lacking. There are very few reports of new mole-
cules with new targets that are effective in vivo. Bedaquiline, a
diarylquinoline that targets bacterial ATP synthase, was recently
provisionally registered by the Food and Drug Administration
and is the only candidate molecule in clinical trials that has both
a clearly defined and novel target (4). Other compounds in
clinical trials include PA824 and Delaminid, both of which have
complex mechanisms and targets that have not been clearly de-
fined, and Linezolid, a ribosomal inhibitor that has been repur-
posed for M. tuberculosis treatment (8, 9). Molecules that inhibit
new targets and have demonstrated efficacy in animals, but are
not yet in clinical trials, include Benzothiazinones that target
decaprenylphosphoryl-β-d-ribose 2′-epimerase (DprE1) (2) and
inhibitors of malate synthase, a glyoxylate shunt enzyme (10). In
addition to their potential as drug candidates, these molecules
are significant for having facilitated the identification of novel
targets for further efforts geared toward drug discovery.
Herein, we report the identification of a small molecule that
kills M. tuberculosis by inhibiting FadD32, an enzyme required
for mycolic acid biosynthesis, using an unbiased whole-cell
screening approach. Although FadD32 is not targeted by any
known drug, mycolic acid biosynthesis is one of the few well-
validated pathways in antituberculosis drug development.
Isoniazid (INH), a central component of the more effective
antituberculosis treatment regimens, similarly targets mycolic
acid biosynthesis through inhibition of InhA (11). Because re-
sistance to INH is on the rise worldwide, with an estimated 13%
of tuberculosis cases exhibiting resistance to this important drug,
its long-term utility may be limited. As a result, significant effort
has been directed toward identifying novel inhibitors of InhA
(12–14), including an effort by Glaxo-Smith Kline and the TB
Alliance. Identification of a drug that targets the critical pathway
of mycolic acid biosynthesis at a step that is distinct from InhA,
thereby bypassing INH resistance, would have a major impact on
treatment of MDR and XDR tuberculosis. Importantly, the
FadD32 inhibitor we have identified has activity in animal
models of tuberculosis that is comparable with that of INH.
Results
Identification of a Series of Substituted Coumarin Inhibitors with
Activity Against M. tuberculosis. To identify novel compounds
with antimycobacterial activity, we modified a reported GFP-
based high-throughput assay (15) and screened a total of 20,502
small molecules for their ability to inhibit the growth of the
H37Rv strain of M. tuberculosis (16). The whole-cell GFP-based
assay was designed to identify compounds that target any path-
way essential under in vitro growth conditions. From the primary
screen, a series of four compounds characterized by a 4,6-diaryl-
5,7-dimethyl coumarin core were found to have potent activity
against actively replicating M. tuberculosis (SI Appendix, Fig. S1).
Subsequent chemical optimization and the synthesis of over
40 substituted coumarin analogs of the initial screening hits
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led to the development of a panel of compounds with increased
potency (17–19) (SI Appendix, Fig. S2). The most potent analog,
coumarin core analog 34 (CCA34), had a minimum inhibitory
concentration (MIC) of 0.24 μM against H37Rv M. tuberculosis
(Fig. 1). CCA34 also had good activity against clinical isolates ofM.
tuberculosis, with MICs against five independent isolates ranging
from 0.33 to 0.57 μM (SI Appendix, Table S1) and M. tuberculosis
strains with monoresistance to the clinically relevant drugs INH,
rifampicin, streptomycin, and ciprofloxacin (SI Appendix, Table S1
and Fig. S3). Substituted coumarins had bactericidal activity and
CCA34 decreased bacterial numbers by over four logs within
3 d of treatment (SI Appendix, Fig. S4A). The minimum bac-
tericidal concentration (MBC) of CCA34 was determined to
be 1.9 μM, which is comparable with the 0.5 μM MBC of INH.
Previous screens for antitubercular compounds have resulted in
the identification of small molecules whose activity is dependent
on the carbon source present in the growth medium. In particular,
growth on standard glycerol containing media results in the iden-
tification of inhibitors that induce “self-poisoning” ofM. tuberculosis
by promoting the accumulation of glycerol phosphate and rapid
ATP depletion (20). Inhibitors with this mechanism of action
(MOA) are devoid not only of activity on other carbon sources,
but notably, of in vivo efficacy. We therefore tested CCA34 ac-
tivity on alternate carbon sources and found that it was equally
active when acetate or valerate was used as the sole carbon source
in the growth medium (SI Appendix, Fig. S4B), demonstrating that
these inhibitors have carbon-source independent activity.
Currently there is interest in the identification of inhibitors with
activity against M. tuberculosis cultured in nonreplicating states in
vitro, as the bacilli are proposed to potentially enter a dormant,
nonreplicating state in vivo that may contribute to latent infection
(21). Carbon-starved M. tuberculosis is one such model (22). We
tested CCA34 for activity against carbon-starved M. tuberculosis
and found that it had low but detectable activity against non-
replicating carbon-starved M. tuberculosis (SI Appendix, Fig. S4C),
decreasing bacterial numbers in starved cultures by one log when
used at the MIC against replicating cells. Substituted coumarins
therefore have only limited activity against nonreplicating cells,
as is similarly observed with all current antitubercular antibiotics.
In addition to their potency, the substituted coumarins were
highly species-selective. The compounds were active against
Mycobacterium bovis bacillus Calmette–Guérin, Mycobacterium
avium, Mycobacterium marinum, and Mycobacterium intracellulare,
mycobacterial species that are closely related to M. tuberculosis,
but were inactive against more distantly related mycobacterial
species (SI Appendix, Table S1). In addition, these compounds
exhibited no activity against any Gram-positive or Gram-negative
bacterial species tested (SI Appendix, Table S1), indicating that
the target of these compounds may be unique to mycobacteria.
Mutation of fadD32 confers resistance to substituted cou-
marins. Generating resistance to an antibiotic followed by next-
generation sequencing to identify the basis of resistance has
been one useful approach to facilitate target identification of
novel small molecules (2, 4). To identify the target of the substituted
coumarins, we generated resistance to two analogs identified in
the original screen, CCA1 and CCA2. Resistant mutants were
generated by plating M. tuberculosis on solid 7H10 media con-
taining 10× the MIC of each compound. Resistance was ob-
served at a frequency of 1 × 10−7, a rate that is comparable with
that of other clinically used drugs including rifampicin (3 × 10−8)
and ethambutol (1 × 10−7), and an order of magnitude lower
than observed for INH (1 × 10−6). These mutants had MICs at
least 10-fold higher than the parent strain (Fig. 2A) and were
resistant to all of the substituted coumarin analogs tested (Fig. 2
A and B and SI Appendix, Fig. S5 A and B).
To identify the target of the coumarin analogs, we sequenced
the genomes of four of the resistant mutants using Illumina se-
quencing technology and compared the genome of each mutant
to the parent clone used in the individual selections (23). Point
mutations in a single gene, fadD32, were associated with re-
sistance to the substituted coumarins (SI Appendix, Table S2).
Interestingly, relatively few mutations were identified in each
resistant mutant, with two mutant genomes containing only a
single point mutation in fadD32. Mutations in fadD32 associated
with resistance were found in two codons, E120 and F291, re-
sulting in point mutants E120A, E120V, and F291L. To confirm
that these mutations were responsible for conferring resistance
to the coumarin inhibitors, the mutant alleles E120A and F291L
were expressed in wild-type M. tuberculosis. Episomal expression
of either mutant but not wild-type FadD32 protein was sufficient
to confer resistance to substituted coumarins in the presence of
endogenous wild-type FadD32, suggesting that the E120A and
F291L alleles are dominant (Fig. 2 A and B and SI Appendix,
Fig. S5 A and B). These data suggest that substituted coumarins
killM. tuberculosis by inhibiting FadD32, and that FadD32 may
be a good target for antitubercular activity.
The 4,6-diaryl-5,7-dimethyl coumarins represent a unique
structural class of compounds with activity against M. tuber-
culosis. Other compounds with a coumarin structural scaffold
have been reported to have activity against M. tuberculosis (24–
26), including novobiocin, an antibiotic that targets bacterial
DNA gyrase. We tested whether our CCA1 and CCA2 mutants
were cross-resistant to novobiocin. None of the fadD32 mutants
had increased resistance to novobiocin (SI Appendix, Fig. S6),
demonstrating that these compounds act by a mechanism that is
distinct from that of novobiocin and confirming that the presence
of a coumarin acts as a scaffold, with the substituents providing
target specificity. Structure activity relationship (SAR) analysis
also demonstrates that the coumarin analogs identified in our
screen represent a unique structural series. We found that the
presence of the R1 and R3 aromatic substituents is required for
antimycobacterial activity (SI Appendix, Table S3). In addition,
both the R2 and R4 methyl substituents are important con-
tributors as substitution of either of these methyl groups with
a hydrogen atom results in a >10-fold loss of activity (SI Ap-
pendix, Table S3). The requirement for the methyl groups may
be due to the impact of the methyl groups on the torsion angles
of the two biaryl substituents relative to the coumarin ring (SI
Appendix, Fig. S7).
The 4,6-diaryl-5,7-dimethyl coumarins inhibit mycolic acid
biosynthesis. FadD32 is an essential enzyme (27, 28) that plays
a critical role in the biosynthesis of mycolic acids, branched
fatty acids consisting of a very long meromycolate chain (C54
to C63) and a shorter alpha alkyl chain (C22 to C24) (29) that
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Fig. 1. Structures of substituted coumarin analogs and MICs against
M. tuberculosis H37Rv. The MIC was defined as the concentration at which
bacterial numbers were reduced to 99% of untreated control after 14 d of
treatment. Bacterial numbers were assessed by plating for cfu.
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are the major component of the unique mycobacterial cell
wall. They are primarily found as an arabinogalactan-mycolate
species covalently linked to the inner peptidoglycan layer, and
as a component of a free glycolipid, trehalose dimycolate (TDM),
that is a major component of the outer mycomembrane (29).
FadD32 is required to activate meromycolic acids to facilitate
their condensation with a shorter fatty acid, resulting in the
final beta-keto-alpha alkyl mycolic acid. FadD32 has two en-
zymatic functions. Its fatty acyl-AMP ligase (FAAL) activity
first adenylates meromycolic acids generated by the fatty acid syn-
thase (FAS) II biosynthetic pathway, and its fatty acyl ACP syn-
thetase (FAAS) activity results in the transfer of the activated
intermediate to the ACP domain of the condensing enzyme poly-
ketide synthase 13 (PKS13) (30, 31) (Fig. 3A).
FadD32 is downstream of InhA in the biosynthetic pathway of
mycolic acids, and an INH-resistant clinical isolate with an inhA
promoter mutation [C(-15)T] remains susceptible to coumarin
inhibitors (SI Appendix, Table S1), as are INH-resistant katG
mutants (SI Appendix, Fig. S3). The lack of cross-resistance be-
tween INH and CCA34 resistant mutants likely explains the
observation that we were unable to generate resistant mutants in
the presence of both drugs. In addition, we examined the inter-
action of CCA34 with currently used antituberculosis (anti-TB)
drugs, including INH, ethambutol, ethionamide, and rifampicin,
and found no evidence of synergy or antagonism [fractional in-
hibitory concentration (FIC) < 4 for all drugs; SI Appendix].
However, as substituted coumarins and INH both inhibit targets
within the same critical pathway for cell wall biosynthesis, they
would be expected to result in similar phenotypic changes to M.
tuberculosis. This prediction was confirmed in the similar tran-
scriptional profile observed for cells treated with subinhibitory
concentrations of coumarin inhibitors and INH. Many INH-
responsive genes are also regulated in response to coumarin
inhibitors, including iniA-iniC, fas, pks13, and fadD32 (32) (SI
Appendix, Table S4). Similarly, because mycolic acids are critical
structural components of the mycobacterial cell wall, treatment
with inhibitors of mycolic acid biosynthesis, regardless of the step
that is inhibited, should result in comparable alterations in cell-
wall architecture. Treatment of bacterial cells with sublethal
concentrations of either INH or CCA2 resulted in strikingly similar
phenotypic changes to the cell wall of M. tuberculosis characterized
by loss of the outer electron opaque layer, a thickening of the inner
electron opaque layer, and a general rounding of the cell body
(SI Appendix, Fig. S8).
To directly determine whether 4,6-diaryl-5,7-dimethyl cou-
marin inhibitors affect mycolic acid biosynthesis, we treated
M. tuberculosis with 1× or 5× the MIC of CCA2 or CCA34 and
monitored production of mycolic acids by TLC using [14C]acetate
for labeling. Radiolabeled acetate was added concurrently with
inhibitor such that mycolic acids visualized result from synthesis
that occurs during the treatment period. We saw that treatment
with CCA2 or CCA34 resulted in a striking decrease in the amount
of mycolic acids that were synthesized during the treatment time.
Treatment with substituted coumarin inhibitors blocked mycolic
acid synthesis as effectively as did INH (Fig. 3B).
The 4,6-diaryl-5,7-dimethyl coumarins directly inhibit the
FAAS activity of FadD32. To conclusively demonstrate that
FadD32 is the target of these substituted coumarins, we turned
to biochemical assays of FadD32 function assesing the two in-
dividual steps catalyzed by FadD32 (31). In the first assay, we
tested the FAAL activity of the purified enzyme by monitoring
formation of acyl-AMP from [14C]myristic acid and ATP using
TLC. As a control, we used the known reaction intermediate
mimetic adenosine 5′-dodecylphosphate (AMPC12) (31), a sub-
strate analog that has no activity against intactM. tuberculosis but
as expected partially inhibits the FAAL activity ofM. tuberculosis
FadD32 (Fig. 3C). The FAAL reaction was not inhibited by
treatment with CCA34 (Fig. 3C), even at the high concentration
of 100 μM, indicating that these inhibitors do not affect the
FAAL activity of FadD32. To assess the impact of the coumarin
inhibitors on the FAAS activity of the enzyme, we next assayed
the second step of FadD32, by monitoring acylation of the my-
cobacterial acyl carrier protein (AcpM) with [14C]acyl-AMP
generated from [14C]myristic acid via the acyl-AMP intermediate.
We found that CCA34 inhibits the formation of the [14C]acyl-
AcpM adduct (Fig. 3D and SI Appendix, Fig. S9), indicating that
these molecules function by inhibiting the ability of FadD32 to
transfer the activated intermediate to the ACP domain of PKS13.
Similar to previous reports (31), we observed acylated FadD32 in
this assay (Fig. 3E and SI Appendix, Fig. S9) (31), which was also
inhibited by treatment with CCA34. In contrast, the substituted
coumarins were unable to inhibit formation of the intermediate
acylated FadD32 or the final [14C]acyl-AcpM product when the
FadD32F291L mutant was tested, further supporting the mech-
anism of action as well as validating the mechanism of resistance.
The 4,6-diaryl-5,7-dimethyl coumarin inhibitors effectively
block bacterial replication in vivo via inhibition of FadD32. The
1.0
0.2
0.4
0.6
0.8
0 50 100 150
[CCA2] µM
1.2
0
006
D
O
A
0
0
[CCA34] µM
006
D
O
B
C
5 201510
1.0
0.2
0.4
0.6
0.8
1.2
WT
mutant CCA1-2
mutant CCA2-2
FadD32E120A
FadD32F291L
FadD32
WT
mutant CCA1-2
mutant CCA2-2
FadD32E120A
FadD32F291L
FadD32
6
5
4
3
gol
UF
C 01
0 1 2 3 4
DMSO
10x CCA34
50x CCA34
10x INH
50x INH
days
Fig. 2. Activity of substituted coumarins in vitro and in macrophages. Mu-
tants selected on substituted coumarin inhibitors and WT M. tuberculosis
expressing mutant FadD32 episomally are resistant to high concentrations of
(A) CCA2 and (B) CCA34. (C) Substituted coumarin inhibitors are effective at
treating infected human PBMC derived macrophages. For the macrophage
infection experiment, macrophages were infected at MOI = 1 and were carried
out for 3 d. All treatments relative to DMSO control gave P < 0.02 (n = 3) by
the Mann–Whitney U test. All experiments were repeated a minimum of three
times, and a representative experiment is shown. Error bars are SD.
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identification of a novel target for drug development requires
both chemical and biological validation. Although discovery of
a small molecule inhibitor of a specific target that is able to kill the
bacterium provides chemical validation, demonstration of the
essentiality of that target in animal models is particularly critical
in the case of M. tuberculosis. Because of the strong biological
validation provided by INH for inhibition of mycolic acid bio-
synthesis in TB therapy, we next turned to investigate the activity
of CCA34 against FadD32 in in vivo infection models.
To evaluate the efficacy of these inhibitors against intracellular
M. tuberculosis, human peripheral blood mononuclear cell (PBMC)-
derived macrophages were infected withM. tuberculosis and treated
with INH or CCA34 for 3 d. CCA34 inhibited bacterial replica-
tion when used at the MIC against cells grown in axenic culture.
At higher concentrations, CCA34 was able to kill intracellular
bacteria, reducing the population by one log (Fig. 2C) while
having no effect on macrophage viability (SI Appendix, Fig. S10).
This activity profile compares favorably with that of INH and
demonstrates that the FadD32 is a relevant target during intra-
cellular growth in human macrophages.
Infection of zebrafish embryos (Danio rerio) with M. marinum
is a useful model for studying mycobacterial infection, with many
important characteristics that parallel M. tuberculosis infection in
humans (33). Recently, it has been used to demonstrate the
activity of antitubercular compounds with M. marinum activity
(34) and potentially provides a facile means to perform initial in
vivo testing of novel compounds. The M. marinum ortholog of
FadD32 is highly conserved relative to M. tuberculosis FadD32
(94% identical over 627 amino acids). We therefore used the
zebrafish model for preliminary evaluation of the efficacy of the
substituted coumarin inhibitors in an in vivo infection model.
Zebrafish embryos were infected 50 h post fertilization (hpf) with
M. marinum expressing GFP and then immediately immersed in
water containing inhibitor for 72 h, at which time bacterial
growth was assessed by imaging. The minimum concentration
that prevented bacterial replication was 15 μM, ∼20× the MIC
of CCA34 against M. marinum grown in axenic culture, which
was used in all subsequent experiments. For comparison, we
used 250 μM INH (∼30× the MIC in axenic culture), a concen-
tration that was previously reported to effect maximal bacterial
killing (34). Embryos treated with CCA34 had no observable
bacteria as detected by fluorescence (Fig. 4A). To determine
whether the inhibition of bacterial proliferation by the coumarin
inhibitors could prolong survival of infected embryos, infected
embryos were maintained for an additional 8 d after treatment
with CCA34. Infected fish treated for 3 d with CCA34 had a
statistically significant survival advantage over fish left untreated
(P < 0.0001; log-rank test).
Although this observed efficacy suggests that FadD32 is es-
sential during infection, the observed efficacy could be due, at
least in part, to off-target effects in vivo. One advantage of the
zebrafish embryo model is that it allows for the maintenance of
constant designated CCA34 concentrations that facilitates the
ability to distinguish between sensitive and resistant alleles. To
demonstrate that bacterial clearance and embryo survival were
due to an on-target effect of FadD32 inhibition, we generated
an M. marinum strain that is resistant to substituted coumarin
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vivo infection. (A) CCA34 prevents replication of M. marinum in zebrafish.
Treatment of infected zebrafish with 15 μM CCA34 inhibits bacterial pro-
liferation. (B) Mutation of FadD32 confers resistance to CCA34 in vivo. Fish
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mouse model of tuberculosis. BALB/C mice infected with M. tuberculosis via
aerosol were treated with INH (25 mg/kg) or CCA34 (35 mg/kg) beginning on
day 7 after infection (indicated by the black arrow) for a total of 7 d. Error
bars are SD. *P < 0.02 (n = 5) using the Mann–Whitney U test. A represen-
tative experiment of two is shown.
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inhibitors and repeated the infection experiment. This resistant
mutant possesses a mutation in fadD32 that corresponds to an
amino acid change Y513H (SI Appendix, Fig. S11). We infected
embryos with wild-type M. marinum or the resistant FadD32
mutant. We observed that, in contrast to infection with wild-type
M. marinum, bacterial numbers of the mutant are not signifi-
cantly decreased upon CCA34 treatment (Fig. 4B). Moreover,
embryos infected with the FadD32 resistant mutant succumbed
to infection with the same kinetics as the untreated wild-type.
(P < 0.0001; log-rank test) (Fig. 4C). FadD32 is therefore re-
quired for M. marinum growth in zebrafish embryos, and cou-
marin inhibitors are able to penetrate host tissues and effectively
inhibit proliferation of bacteria via inhibition of FadD32.
Mice are the most commonly used animal model for studying
M. tuberculosis infection and for testing new small molecule in-
hibitors. To further validate FadD32 as a promising target for
the development of antitubercular therapeutics and to provide a
preliminary evaluation of the potential of substituted coumarins
for in vivo efficacy, we tested CCA34 in the mouse tuberculosis
model of infection. Preliminary studies in mice showed that
CCA34 was relatively nontoxic and well tolerated, and an ap-
propriate dosing regimen was developed (SI Appendix, Discussion
and Fig. S12). We next tested CCA34 in BALB/C mice infected
with the Erdman strain of M. tuberculosis via inhalation of
aerosolized bacteria. CCA34 or INH was administered by i.p.
injection beginning 1 wk after initial infection. Four doses of
CCA34 (35 mg/kg) were administered over a 1-wk period with
every-other-day i.p. injection. After 4 d of treatment, there was
a fourfold reduction in bacterial numbers in the lungs of CCA34-
treated mice compared with DMSO-treated control mice, and,
after 8 d, a 30-fold reduction was observed, demonstrating that
CCA34 inhibits bacterial proliferation during infection of mice
(Fig. 4D). The efficacy of CCA34 observed in this short-course
experiment was comparable with that of INH, further supporting
the idea that targeting FadD32 is a valid and potentially prom-
ising therapeutic strategy.
Discussion
In this study, we have identified a series of unique 4,6-diaryl-5,
7-dimethyl coumarins that target a step in mycolic acid synthesis
that is distinct from that targeted by the well-established TB drug
INH and have demonstrated that targeting FadD32 is effective
at treating infection in vivo. FadD32 is a member of the long
chain fatty acyl-AMP ligase (FAAL) family in M. tuberculosis
that functions to adenylate a long-chain fatty acid and then
transfer this activated intermediate to the polyketide synthase
PKS13. Transfer of the activated fatty acid to a PKS is a novel
function for FAAL proteins recently described for a subfamily
of these enzymes found inM. tuberculosis (30, 35), as most members
of this family form acyl-CoA thioesters. The mechanistic basis
for the different enzymatic activity of FadD32 and related family
members is as yet incompletely understood. Notably, these
coumarins specifically inhibit the unique step of these enzymes,
the acylation of an ACP domain of a PKS, suggesting that these
inhibitors will be valuable tools for the investigation of the en-
zymatic function of this important family of enzymes.
This work establishes FadD32 as a validated in vivo target for
M. tuberculosis drug discovery. Using both M. marinum infection
of zebrafish embryos and M. tuberculosis infection of mice, we
find that CCA34 is able to effectively inhibit bacterial prolifer-
ation. Further, zebrafish embryos provide a facile model that
allowed us to demonstrate that CCA34 is on-target during in
vivo infection.
Our mouse data demonstrate that inhibition of FadD32 by
CCA34 can effectively prevent M. tuberculosis replication in a
mammalian model of tuberculosis. Although CCA34 has yet to
be maximally optimized for in vivo efficacy, these initial proof-of-
principle studies provide important validation of Fad32 as a
valuable in vivo target and motivation for further studies. Opti-
mization of the therapeutic properties of 4,6-diaryl-5,7-dimethyl
coumarins, coupled with investigation of these inhibitors in
additional in vivo models, may result in exciting new leads for
drug development. In addition, the validation of FadD32 as
a “druggable” target should spur research into novel compound
series that also target this important enzyme. A recent report of
the development of a high-throughput screening assay against
Mycobacterium smegmatis FadD32 suggests the possibility that
additional inhibitors that target M. tuberculosis FadD32 could be
identified using an enzymatic assay (36). Early testing against
intact M. tuberculosis is important given known difficulties of
translating hits from enzymatic assays into leads with activity
against whole cells (37). Finally, our study confirms the concept
that targeting unique steps in a biosynthetic pathway that is al-
ready targeted by a current antibiotic is an effective strategy for
antituberculosis drug discovery. In the current debate surrounding
antibiotic discovery of whether efforts should be focused on “old”
targets that are well validated by current antibiotics or “new”
targets that would circumvent existing antibiotic resistance, this
work demonstrates that an effective compromise can be found
by targeting unique steps in validated pathways, thereby taking
advantage of prior validation without preexisting resistance. In that
not all essential steps in a biosynthetic pathway can be easily or
equally inhibited with a small molecule, this work demonstrates that
FadD32 can in fact be targeted efficiently for bactericidal effect.
Inhibition of cell-wall synthesis is a cornerstone of antimicro-
bial therapy, with the inhibition of mycolic acid biosynthesis by
INH historically forming a central component of most standard
antitubercular regimens. Although there is much current interest
in targeting nonreplicating states ofM. tuberculosis in the context
of shortening TB therapy and managing latent infection (38), it is
notable that, despite limited nonreplicating activity in vitro, INH
has been important in reducing transmission due to its early
bactericidal activity and rapid clearing of sputum (39), and its
effective use in treating latent infection (40). Thus, the loss of
INH to rising resistance rates creates a major gap in the man-
agement of TB, increasing the urgency for new drugs that can
quickly fill its role. Strategically, targeting novel steps in vali-
dated pathways has the clear advantages of a high likelihood of
therapeutic efficacy, while bypassing existing resistance to cur-
rent pathway inhibitors. Our work demonstrates that FadD32 is
a unique target in a validated pathway with significant promise.
Thus, the chemical and biological validation of FadD32 as an
essential protein and therapeutic target opens up an important
avenue for the development of therapeutics.
Materials and Methods
Bacterial Strains and Growth Conditions. TB strains used were H37Rv, Erdman,
mc26020 (lysine/pantothenate auxotroph), or specified clinical isolates
obtained from the Massachusetts Supranational TB Reference library.
The following strains were also used: bacillus Calmette–Guérin Pasteur,
M. smegmatis MC2155, M. marinum strain M, Escherichia coli K12, Vibrio
cholerae strain 0395, Pseudomonas aeruginosa PA14. For Staphylococcus
aureus and Enterococcus faecalis, clinical isolates were used. M. tuberculosis
H37Rv strains expressing GFP, WT FadD32, or mutant FadD32 were con-
structed using a pUV15tetORm derivative (41) with the tet repressor deleted
for constitutive expression. Mycobacterial strains were cultured in
Middlebrook 7H9 medium with 0.05% Tween 80 and oleic acid/albumin/
dextrose/catalase (OADC) supplement. Cultures were starved for 5 wk in star-
vation medium (7H9 medium with no added glycerol and 0.05% tyloxapol).
Determination of IC90s, MICs, and Small Molecule Inhibition Assays. For deter-
mination of IC90, and for assessing resistance, OD600-based assays were used.
Bacteria were grown to midlog phase and plated in 96-well plates at OD600 =
0.025 in the presence of small molecule inhibitors for indicated time periods,
and growth was assessed by reading OD600. The IC90 value was determined
as the lowest concentration that inhibited growth by 90% relative to the
DMSO control. For MIC determinations, cultures were set up as described
above; however, plates were incubated for a total of 14 d, at which time
bacteria were plated on agar plates for enumeration of cfu. The MIC was
determined as the concentration of inhibitor that resulted in 99% inhibition
of growth relative to the DMSO control. The IC90 and MIC values given are
the average from a minimum of two and up to five experiments.
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Macrophage Infection Assays. Human peripheral blood monocytes were iso-
lated and differentiated in 25 ng/mL human macrophage colony stimulating
factor (MCSF). After 5 d, the cells were washed with PBS and infected with
M. tuberculosis at a multiplicity of infection (MOI) = 1 in DMEM plus 5%
(vol/vol) FBS/5% (vol/vol) horse serum. The infection was carried out for 4 h,
at which time the monolayer was washed once and RPMI with DMSO or
inhibitor was added. After 3 d, the cells were washed with PBS and lysed in
water plus 0.5% Triton X-100. Dilutions of lysate were prepared in PBS plus
0.05% Tween 80 and were plated onto agar 7H10 plates for enumeration.
In Vitro Assays of FadD32 Function. His-tagged FadD32 WT and mutant pro-
teins were expressed in Tuner DE3 cells (EMD Chemicals), which were were
grown at 30 °C overnight with 1mM isopropyl β-D-1-thiogalactopyranoside
(IPTG). Cells were lysed in 50 mM Tris, pH 7.5, 500 mM NaCl, 10 mM imidazole,
and 0.75 mg/mL lysozyme by sonication. Lysate was purified over nickel
nitrilotriacetic acid (Ni-NTA) agarose with 250 mM imidazole elution fol-
lowed by desalting with 10G desalting column (Bio-Rad), and protein was
eluted into 50 mM Tris, pH 7.5, 500 mM NaCl. AcpM was purified as described
for FadD32 with 3 h IPTG induction at 37 °C. FAAL assays were performed as
previously described (31). FAAS assays were performed as described (31) with
the following modifications. The reaction mixture consisted of 100 μM [1-14C]
myristic acid, 2 mM DTT, 10 mM MgCl2, 5 mM ATP in 20 mM Hepes, 5 μM
FadD32, and 5–10 μM AcpM. Reactions were incubated for 16 h at 30 °C and
analyzed by SDS/PAGE using a 10–20% gel. Quantitation of the transfer of the
acyl-AMP onto AcpM was achieved using phosphorimaging.
Infections of Zebrafish and Mice. Infection of zebrafish with M. marinum/GFP
was carried out as described previously (34, 42). Zebrafish embryos from the
AB line staged 50 hpf were microinjected withM. marinum/GFP into the yolk
circulation valley. Infected embryos were immediately immersed in embryo
medium (E3) containing inhibitor or DMSO control and incubated at 29 °C.
Fluorescent images were acquired using a Zeiss DiscoveryV.12 stereomicroscope
and analyzed using CellProfiler. For time-to-death experiments, infected em-
bryos were exposed to inhibitor for a period of 3 d, after which time embryos
were maintained in media without inhibitor for the duration of the experiment.
Embryos were observed every day for survival with the scoring of living versus
dead being ascertained by the presence of a heartbeat and circulating blood
under a stereomicroscope. For mouse infections, bacteria were grown to midlog
phase and sonicated to remove clumps. BALB/C mice were infected with ∼80 cfu
of Erdman M. tuberculosis via the aerosol route using a Madison chamber
(University of Wisconsin, Madison, WI). Compounds were administered by i.p.
injection in a total volume of 100 μL of DMSO. Organs were homogenized
in PBS plus 0.05% Tween 80 and plated onto 7H10 agar enriched with 10%
OADC (Difco) for enumeration of cfu. All experiments performed using
mice were approved by the Harvard Medical Area Standing Committee on
Animals. All zebrafish experiments were approved by the Massachusetts
General Hospital Institutional Animal Care and Use Committee.
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